– Endocrinology clinical development progress and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
– Phase 3 Week 52 data for TransCon™ PTH in adults with hypoparathyroidism selected for oral presentation
COPENHAGEN, Denmark, June 13, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome at ENDO 2023, the annual meeting of the Endocrine Society being held June 15-18 in Chicago.
An oral presentation on Saturday, June 17, will feature Phase 3 Week 52 data for TransCon PTH in adults with hypoparathyroidism, and five additional poster presentations listed in the table below will showcase other Ascendis programs and data. In addition, Ascendis will host booth #1628, booth #1740, and two product theaters during ENDO 2023.
| ABSTRACT | PRESENTING AUTHOR | |
| Hypoparathyroidism | ||
| Long-Term Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results from the Open-Label Extension of the PaTHway Phase 3 Trial
Oral presentation, Saturday, June 17, 4:30-4:45 pm (CDT)) |
Bart L. Clarke, M.D. | |
| Clinical and Economic Burden of Postsurgical Chronic Hypoparathyroidism: A U.S. Medicare Retrospective Analysis
Poster, Saturday, June 17, 1:00 – 2:00 pm (CDT) |
Wahidullah Noori, Pharm. D., M.S. |
|
| Achondroplasia | ||
| Significantly Improved Annual Height Velocity with Once-Weekly TransCon CNP in Children with Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
Poster, Thursday, Thursday, June 15, 12:30 – 1:30 pm (CDT) |
Ravi Savarirayan, MBBS, FRACP, HGSA, MD | |
| Growth Hormone Deficiency | ||
| Prevalence of Comorbidities Among Treated and Untreated Adults with Suspected Growth Hormone Deficiency
Late Breaker: Poster, Saturday, June 17, 1:00 – 2:00 pm (CDT) |
Subhara Raveendran, Ph.D | |
| Subanalysis by Tanner Stage in Phase 3 Trials in Children and Adolescents with Growth Hormone Deficiency Treated with Lonapegsomatropin
Poster, Thursday, June 15, 12:30 – 1:30 pm (CDT) |
Paul Hofman, MBChB, Dip Obs, FRACP | |
| Turner Syndrome | ||
| Design of the New InsiGHTS Trial: A Multicenter, Phase 2, Randomized, Open-Label, Active Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Lonapegsomatropin in Prepubertal Individuals with Turner Syndrome
Poster, Thursday, June 15, 12:30 – 1:30 pm (CDT) |
Sohair Abdelrahman, Pharm.D | |
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Germany (Heidelberg, Berlin and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey). Visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated, global biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in its development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on its business from the worldwide COVID-19 pandemic and ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2023 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © June 2023 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: | ||
| Tim Lee | Melinda Baker | ||
| Ascendis Pharma | Ascendis Pharma | ||
| +1 (650) 374-6343 | +1 (650) 709-8875 | ||
| tle@ascendispharma.com | media@ascendispharma.com | ||
| ir@ascendispharma.com | |||
| Patti Bank | |||
| ICR Westwicke | |||
| +1 (415) 513-1284 | |||
| patti.bank@westwicke.com |
